Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
JFrog Ltd (FROG) is a leading software-application business based in the US. It opened the day at $47.27 after a previous close of $46.81. During the day the price has varied from a low of $45.81 to a high of $47.31. The latest price was $46.05 (25 minute delay). JFrog is listed on the NASDAQ and employs 700 staff. All prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Open | $47.27 |
|---|---|
| High | $47.31 |
| Low | $45.81 |
| Close | $46.05 |
| Previous close | $46.81 |
| Change | $-0.76 |
| Change % | -1.6236% |
| Volume | 444,091 |
| 52-week range | $31.17 - $95.20 |
|---|---|
| 50-day moving average | $35.96 |
| 200-day moving average | $42.29 |
| Wall St. target price | $53.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.38 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $46.05 from 2021-10-15
| 1 week (2021-10-08) | 37.67% |
|---|---|
| 1 month (2021-09-16) | 27.88% |
| 3 months (2021-07-16) | 5.98% |
| 6 months (2021-04-16) | -10.08% |
| 1 year (2020-10-16) | -42.57% |
|---|---|
| 2 years (2019-10-12) | N/A |
| 3 years (2018-10-12) | N/A |
| 5 years (2016-10-12) | N/A |
| Revenue TTM | $175.3 million |
|---|---|
| Gross profit TTM | $122.4 million |
| Return on assets TTM | -4.65% |
| Return on equity TTM | -8.45% |
| Profit margin | -17.13% |
| Book value | $5.98 |
| Market capitalisation | $3.2 billion |
TTM: trailing 12 months
There are currently 6.9 million JFrog shares held short by investors – that's known as JFrog's "short interest". This figure is 6.5% up from 6.5 million last month.
There are a few different ways that this level of interest in shorting JFrog shares can be evaluated.
JFrog's "short interest ratio" (SIR) is the quantity of JFrog shares currently shorted divided by the average quantity of JFrog shares traded daily (recently around 784506.11551529). JFrog's SIR currently stands at 8.83. In other words for every 100,000 JFrog shares traded daily on the market, roughly 8830 shares are currently held short.
To gain some more context, you can compare JFrog's short interest ratio against those of similar companies.
However JFrog's short interest can also be evaluated against the total number of JFrog shares, or, against the total number of tradable JFrog shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case JFrog's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 JFrog shares in existence, roughly 70 shares are currently held short) or 0.1451% of the tradable shares (for every 100,000 tradable JFrog shares, roughly 145 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against JFrog.
Find out more about how you can short JFrog stock.
We're not expecting JFrog to pay a dividend over the next 12 months.
JFrog Ltd. provides DevOps platform to achieve continuous software release management platform enabling organizations to deliver software updates across any system in the United States. Its platform acts as a bridge between software development and deployment, which enables organizations to build and release software faster and securely. The company's products include JFrog Artifactory, a package repository that allows teams and organizations to store, update, and manage their software packages at any scale; JFrog Pipelines, an integration/continuous delivery tool for automating and orchestrating the movement of software packages; JFrog Xray, which scan JFrog Artifactory to secure all packages stored in it; JFrog Distribution that provides software package distribution with enterprise-grade performance; JFrog Artifactory Edge that utilizes and leverages metadata from JFrog Artifactory to facilitate the transfer of the incremental changes in software packages from their previous versions; JFrog Mission Control, a platform control panel that provides a view of moving pieces of an organization's CSRM workflow; and JFrog Insight, a DevOps intelligence tool. Its products also comprise JFrog Pro, JFrog Pro X, JFrog Enterprise, JFrog Pro Team, and JFrog Enterprise Plus products that offer ongoing updates, upgrades, and bug fixes, as well as cluster configuration, multi-site replication, and SLA support. The company serves technology, financial services, retail, healthcare, and telecommunications organizations. JFrog Ltd.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
